Translating Science
into Medicine
From molecular insight to clinical possibility, Oscotec advances breakthrough science into innovative medicines for patients with unmet medical needs.
Latest News
Mission
Translating Science into Medicine
Founded in 1998, Oscotec Inc. is a Korea-based biotechnology company dedicated to discovering and developing innovative medicines. We identify disease-relevant mechanisms, validate drug–target–disease hypotheses, and advance the most promising candidates toward clinical proof-of-concept. Our capabilities span internal drug discovery, translational research, and clinical development, extended through open innovation and global partnerships.
Vision
Global Leader in Translational Innovation
Oscotec is investing in the next generation of innovative medicines, with a particular focus on overcoming cancer therapy resistance and recurrence. We are also selectively pursuing opportunities in areas of high unmet needs where our scientific expertise and development capabilities can create lasting value. Through rigorous science, translational insight, and strategic collaboration, we aim to deliver meaningful and durable benefits to patients worldwide.
Innovative Pipeline
Pipeline
Oscotec’s pipeline advances innovative drug candidates across oncology, immunology, neurodegenerative disease, and renal fibrosis.
From discovery-stage programs to clinical development and marketed assets, we focus on differentiated targets, strong disease biology, and meaningful therapeutic potential to bring scientific innovation closer to patients.
Anti-Cancer Anti-Resistance Therapy
ACART
ACART is designed to block the comeback. We investigate the adaptive cell states that allow a rare population of cancer cells to survive therapy, re-emerge, and seed acquired resistance.
Partnership
